ClinicalTrials.Veeva

Menu

Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract

University Hospital Basel logo

University Hospital Basel

Status

Completed

Conditions

Irritable Bowel Syndrome
Peptic Ulcer
Functional Dyspepsia
Peptic Esophagitis
Inflammatory Bowel Diseases

Study type

Observational

Funder types

Other

Identifiers

NCT00920400
CALPROTECT

Details and patient eligibility

About

Fecal calprotectin is a very sensitive non-invasive inflammation marker in the detection of inflammatory bowel disease and, to a lesser degree, has also proven to be useful in adenomatous polyps, neoplasias, and infectious gastroenteritis. Elevated calprotectin levels can also be found in patients with lesion only in the upper gastrointestinal tract. However, the diagnostic value of calprotectin has never been tested in this setting. The aim of the study is therefore to determine the diagnostic value of fecal calprotectin in patients with diseases of the upper gastrointestinal tract.

Enrollment

287 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients referred for upper gastrointestinal endoscopy for any reason
  • Older than 18 years

Exclusion criteria

  • Patients who are not able to provide informed consent
  • Patients who are not able to provide a stool sample

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems